Forte Biosciences Inc (FBRX)

$27.44 +0.80 (2.98%)
Market Cap 367.42M
Revenue (ttm) 0.00
Net Income (ttm) -35.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 43,339
Avg Vol 130,644
Day's Range N/A - N/A
Shares Out 12.53M
Stochastic %K 58%
Beta 3.25
Analysts Strong Sell
Price Target $63.75

Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 310 618 6994
Address:
3060 Pegasus Park Drive, Building 6, Dallas, United States
G_D_1
G_D_1 Dec. 22 at 4:29 PM
$FBRX $31
0 · Reply
porky1963
porky1963 Dec. 22 at 11:47 AM
$FBRX will ignore pre-market.
0 · Reply
porky1963
porky1963 Dec. 21 at 7:14 PM
$FBRX something in new year i hope.looking good but transactions will be low next 2 weeks,keep an eye on buy to sell ratio,this will give an indication of next few months,high buys i hope .already 5 times its low.so not sure if it will run for a time.
0 · Reply
G_D_1
G_D_1 Dec. 21 at 2:16 PM
$FBRX Any New’s
0 · Reply
porky1963
porky1963 Dec. 21 at 1:27 PM
hope you all kept $FBRX
0 · Reply
ObeCalp
ObeCalp Dec. 19 at 9:30 PM
$FBRX AND $PHAT... Order to buy didn't fill today. Oh, well.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 18 at 8:56 PM
$IFRX Part 2 Hidden Gems according to Guggenheim (don’t shooot messanger): “….where AMGN’s avacopan could limited therapeutic window. IFRX has recently announced positive topline results from the Phase IIa 4-week basket study: (1) In HS, Izicopan demonstrated rapid & compelling efficacy that are aligned with successful biologic comparators, with clear safety and a dose-dependent profile; (2) In CSU, while the efficacy signal is stronger in HS,‘904 drives reduction in UAS7 within a range indicative of clinical activity. Given there is no other development in the oral C5aR space, IFRX could inaugurate a new MoA across this multibillion dollar indication market. Initiation of a Phase II program for Izicopan…. Also mentioned as hidden gems: $RAPT $PHAT $SION $FBRX
1 · Reply
G_D_1
G_D_1 Dec. 18 at 7:23 PM
$FBRX $29
0 · Reply
Doozio
Doozio Dec. 18 at 3:53 PM
$FBRX about it. A new 🧠 $DAWN is 🐒🍌🧠⏰♾️. N it hasn’t even spread on the $DLO yet.
0 · Reply
G_D_1
G_D_1 Dec. 18 at 3:25 PM
$FBRX $26
0 · Reply
Latest News on FBRX
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Dec 22, 2025, 4:01 PM EST - 1 day ago

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Nov 14, 2025, 9:00 AM EST - 5 weeks ago

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Nov 3, 2025, 4:01 PM EST - 7 weeks ago

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Oct 3, 2025, 4:01 PM EDT - 2 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Sep 15, 2025, 9:00 AM EDT - 3 months ago

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Forte Biosciences, Inc. Announces Results and Provides Update

Aug 14, 2025, 4:01 PM EDT - 4 months ago

Forte Biosciences, Inc. Announces Results and Provides Update

Forte Biosciences Announces Pricing of $75 Million Public Offering

Jun 25, 2025, 12:28 AM EDT - 6 months ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Jun 24, 2025, 4:01 PM EDT - 6 months ago

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Jun 23, 2025, 7:18 AM EDT - 6 months ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Mar 31, 2025, 9:00 AM EDT - 9 months ago

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Feb 3, 2025, 9:00 AM EST - 11 months ago

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Forte Biosciences to Host R&D Day December 3, 2024

Nov 25, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences to Host R&D Day December 3, 2024

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 20, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

May 13, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Nov 13, 2023, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 14, 2023, 10:50 AM EDT - 2 years ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Sep 6, 2023, 3:15 PM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 25, 2023, 8:00 AM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

May 15, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Jan 12, 2023, 4:05 PM EST - 3 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Nov 14, 2022, 4:01 PM EST - 3 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 17, 2022, 8:00 AM EDT - 3 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Aug 15, 2022, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Jun 7, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

May 16, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Sep 6, 2021, 12:42 PM EDT - 4 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Why Forte Biosciences Stock Is Down Over 80% Today

Sep 3, 2021, 2:31 PM EDT - 4 years ago

Why Forte Biosciences Stock Is Down Over 80% Today

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 12:19 PM EDT - 4 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 3, 2021, 7:21 AM EDT - 4 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Forte Biosciences Just Plummeted 80%: Here's Why

Sep 2, 2021, 5:47 PM EDT - 4 years ago

Forte Biosciences Just Plummeted 80%: Here's Why

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Sep 2, 2021, 4:05 PM EDT - 4 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Aug 16, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

May 11, 2021, 7:24 AM EDT - 5 years ago

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

May 10, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

May 3, 2021, 4:30 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Apr 9, 2021, 6:07 AM EDT - 5 years ago

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Apr 8, 2021, 6:59 PM EDT - 5 years ago

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

Mar 29, 2021, 12:10 PM EDT - 5 years ago

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

AMGN AXP CAT IMOM JPM UNH VRA

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Mar 24, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Mar 17, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

Feb 23, 2021, 4:01 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

G_D_1
G_D_1 Dec. 22 at 4:29 PM
$FBRX $31
0 · Reply
porky1963
porky1963 Dec. 22 at 11:47 AM
$FBRX will ignore pre-market.
0 · Reply
porky1963
porky1963 Dec. 21 at 7:14 PM
$FBRX something in new year i hope.looking good but transactions will be low next 2 weeks,keep an eye on buy to sell ratio,this will give an indication of next few months,high buys i hope .already 5 times its low.so not sure if it will run for a time.
0 · Reply
G_D_1
G_D_1 Dec. 21 at 2:16 PM
$FBRX Any New’s
0 · Reply
porky1963
porky1963 Dec. 21 at 1:27 PM
hope you all kept $FBRX
0 · Reply
ObeCalp
ObeCalp Dec. 19 at 9:30 PM
$FBRX AND $PHAT... Order to buy didn't fill today. Oh, well.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 18 at 8:56 PM
$IFRX Part 2 Hidden Gems according to Guggenheim (don’t shooot messanger): “….where AMGN’s avacopan could limited therapeutic window. IFRX has recently announced positive topline results from the Phase IIa 4-week basket study: (1) In HS, Izicopan demonstrated rapid & compelling efficacy that are aligned with successful biologic comparators, with clear safety and a dose-dependent profile; (2) In CSU, while the efficacy signal is stronger in HS,‘904 drives reduction in UAS7 within a range indicative of clinical activity. Given there is no other development in the oral C5aR space, IFRX could inaugurate a new MoA across this multibillion dollar indication market. Initiation of a Phase II program for Izicopan…. Also mentioned as hidden gems: $RAPT $PHAT $SION $FBRX
1 · Reply
G_D_1
G_D_1 Dec. 18 at 7:23 PM
$FBRX $29
0 · Reply
Doozio
Doozio Dec. 18 at 3:53 PM
$FBRX about it. A new 🧠 $DAWN is 🐒🍌🧠⏰♾️. N it hasn’t even spread on the $DLO yet.
0 · Reply
G_D_1
G_D_1 Dec. 18 at 3:25 PM
$FBRX $26
0 · Reply
fallondpicks
fallondpicks Dec. 17 at 10:36 PM
19 #stockbreakouts $ABM, $DBVT (gap), $FBRX, $KLRS, $TWO (gap, base and 200-day MA). One sub-$1. Four $1-2.
0 · Reply
DylanGFM
DylanGFM Dec. 17 at 5:04 PM
$FBRX
0 · Reply
G_D_1
G_D_1 Dec. 17 at 4:57 PM
$FBRX $24
0 · Reply
Doozio
Doozio Dec. 16 at 7:08 PM
$FBRX all the way up da Roger without Yo? Bums.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 15 at 3:29 PM
$FBRX Share Price: $21.70 Contract Selected: May 15, 2026 $20 Calls Buy Zone: $5.44 – $6.72 Target Zone: $10.25 – $12.52 Potential Upside: 78% ROI Time to Expiration: 150 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Doozio
Doozio Dec. 13 at 2:58 PM
$XBI it’s only obvious wen it’s obvious n they just said don’t $FOLD on FRYday. don’t even gotta $FBRX etabout or $AXSM body all yo gotta do is wUtch 🐒🍌🧠⏰♾️
0 · Reply
G_D_1
G_D_1 Dec. 12 at 1:08 PM
$FBRX $23
0 · Reply
Doozio
Doozio Dec. 10 at 6:56 PM
$VNDA it was always up da Roger wen a new 🧠 $DAWN became 🐒🍌🧠⏰♾️. $FBRX etaboutit
0 · Reply
G_D_1
G_D_1 Nov. 26 at 3:44 PM
$FBRX $ 22
0 · Reply
Doozio
Doozio Nov. 25 at 5:45 PM
$FBRX et about it ?
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 12:57 PM
Evercore ISI Group has adjusted their stance on Forte Biosciences ( $FBRX ), setting the rating to Outperform with a target price of 65.
0 · Reply
G_D_1
G_D_1 Nov. 25 at 12:54 PM
$FBRX Evercore ISI initiated coverage on Forte Biosciences Inc. (NASDAQ:FBRX) with an Outperform rating and a $65.00 price target, representing potential upside of 250% from the current price of $19.06. The $339.87 million market cap biotech company has analyst targets ranging from $19 to $75, with a strong buy consensus.
0 · Reply